Is Glenmark Pharmaceuticals the Best Stock in Its Sector? A Look at the Numbers

Glenmark Pharmaceuticals CMP Rs 2,272 (13 Oct 2026). Market cap Rs 64,404 Cr. ROE 28.08%. P/E 35.82x versus Industry P/E 36.69x.

Is Glenmark Pharmaceuticals the best stock in its sector? The stock trades on the NSE at Rs 2,272 as of 13 October 2026, within its 52-week range of Rs 1,792.60 to Rs 2,537.60. Glenmark Pharmaceuticals Ltd, headquartered in Mumbai, is a research-led pharmaceutical company with branded generics, specialty products and active ingredients sold in India and global markets.

Glenmark Pharmaceuticals sits in the Healthcare sector, and its 28.08% ROE and 35.82x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.

Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers

Click Here – Get Free Investment Predictions

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd, headquartered in Mumbai, is a research-led pharmaceutical company with branded generics, specialty products and active ingredients sold in India and global markets. Branded formulations in India and emerging markets, along with generics and specialty products, drive its business. The stock trades about 10 percent below its 52-week high and about 27 percent above its 52-week low. At a market capitalisation of Rs 64,404 Cr, it is tracked as part of the Healthcare sector on Univest.

Is Glenmark Pharmaceuticals the Best Stock in Its Sector?

Glenmark Pharmaceuticals makes its case as the best stock in its sector primarily on return on equity and balance sheet strength, combining a 28.08% ROE with a 35.82x P/E against the sector’s 36.69x Industry P/E. Glenmark’s 35.82x P/E is slightly below the 36.69x Industry P/E, backed by a 28.08% ROE that is higher than Zydus Lifesciences at 18.59% and Cipla at 11.27%, though its P/E is above both peers.

Metric	Glenmark Pharmaceuticals
CMP (NSE)	Rs 2,271.50
52-Week High / Low	Rs 2,537.60 / Rs 1,792.60
Market Cap	Rs 64,404 Cr
P/E (TTM) vs Industry P/E	35.82x vs 36.69x
P/B	6.13
ROE	28.08%
EPS (TTM)	Rs 63.70
Dividend Yield	0.22%
Debt to Equity	0.06

Compare Glenmark Pharmaceuticals Against Other Healthcare Sector Stocks

How Glenmark Pharmaceuticals Compares Against Its Healthcare Sector Peers

The table below sets Glenmark Pharmaceuticals against 2 other Healthcare sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.

Company	Market Cap (Rs Cr)	P/E	ROE	Debt to Equity
Glenmark Pharmaceuticals	64,404	35.82	28.08%	0.06
Zydus Lifesciences	1,13,616	24.74	18.59%	0.46
Cipla	1,06,130	31.62	11.27%	0.02
Peer average (2 companies)	–	28.18	14.93%	0.24

Against this peer set, Glenmark Pharmaceuticals’s 28.08% ROE is above the 14.93% peer average, and its P/E of 35.82x runs above the peer average of 28.18x. Glenmark’s 35.82x P/E is slightly below the 36.69x Industry P/E, backed by a 28.08% ROE that is higher than Zydus Lifesciences at 18.59% and Cipla at 11.27%, though its P/E is above both peers.

What Makes Glenmark Pharmaceuticals Worth Watching in Healthcare

• High returns: A 28.08% ROE is the highest among the three pharma companies in this peer set.
• Valuation: A 35.82x P/E is slightly below the 36.69x Industry P/E but above Zydus Lifesciences at 24.74x and Cipla at 31.62x.
• Low leverage: A debt to equity ratio of 0.06 is far lower than Zydus Lifesciences at 0.46.

Glenmark Pharmaceuticals Valuation: Is It Justified?

Glenmark’s 35.82x P/E is slightly below the 36.69x Industry P/E, backed by a 28.08% ROE that is higher than Zydus Lifesciences at 18.59% and Cipla at 11.27%, though its P/E is above both peers. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.

Also read – Is Sun Pharma the Best Stock in Its Sector? A Look at the Numbers

Download the Univest iOS App or Univest Android App to track Glenmark Pharmaceuticals and other Healthcare sector stocks.

How to Track Glenmark Pharmaceuticals Before You Invest

Before deciding whether Glenmark Pharmaceuticals deserves its label as the best stock in its sector for your own portfolio, compare it directly against Healthcare sector peers using the steps below.

1. Open the Univest Screener and search for Glenmark Pharmaceuticals to view live price, valuation ratios, and peer comparisons within the Healthcare sector.
2. Compare its P/E, P/B, and ROE against other Healthcare sector stocks before deciding if the current valuation fits your strategy.
3. Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
4. Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.

Conclusion

Glenmark Pharmaceuticals earns a place in the best stock in its sector conversation on the strength of a 28.08% ROE and a P/E of 35.82x against a 36.69x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.

Is Glenmark Pharmaceuticals the best stock in its sector?

Ans. Glenmark Pharmaceuticals has a 28.08% ROE and trades at 35.82x P/E against a 36.69x Industry P/E, and compares above the peer average ROE of 14.93% in this article’s named comparison, so the answer depends on what an investor is prioritising.

What is the current share price of Glenmark Pharmaceuticals?

Ans. Glenmark Pharmaceuticals was trading at Rs 2,271.50 on the NSE as of 13 October 2026, within its 52-week range of Rs 1,792.60 to Rs 2,537.60.

What sector does Glenmark Pharmaceuticals belong to?

Ans. Glenmark Pharmaceuticals is classified under the Healthcare sector on Univest.

How does Glenmark Pharmaceuticals compare to its sector peers on P/E?

Ans. Glenmark Pharmaceuticals’s P/E of 35.82x is above the 28.18x average of the 2 named peers compared in this article.

What is Glenmark Pharmaceuticals’s return on equity?

Ans. Glenmark Pharmaceuticals reported a return on equity of 28.08%, which is above the 14.93% average of its named peers in this comparison.

Should I invest in Glenmark Pharmaceuticals based on its sector position?

Ans. Glenmark Pharmaceuticals’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.

{“@context”: “https://schema.org”, “@type”: “FAQPage”, “mainEntity”: [{“@type”: “Question”, “name”: “Is Glenmark Pharmaceuticals the best stock in its sector?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Glenmark Pharmaceuticals has a 28.08% ROE and trades at 35.82x P/E against a 36.69x Industry P/E, and compares above the peer average ROE of 14.93% in this article’s named comparison, so the answer depends on what an investor is prioritising.”}}, {“@type”: “Question”, “name”: “What is the current share price of Glenmark Pharmaceuticals?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Glenmark Pharmaceuticals was trading at Rs 2,271.50 on the NSE as of 13 October 2026, within its 52-week range of Rs 1,792.60 to Rs 2,537.60.”}}, {“@type”: “Question”, “name”: “What sector does Glenmark Pharmaceuticals belong to?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Glenmark Pharmaceuticals is classified under the Healthcare sector on Univest.”}}, {“@type”: “Question”, “name”: “How does Glenmark Pharmaceuticals compare to its sector peers on P/E?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Glenmark Pharmaceuticals’s P/E of 35.82x is above the 28.18x average of the 2 named peers compared in this article.”}}, {“@type”: “Question”, “name”: “What is Glenmark Pharmaceuticals’s return on equity?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Glenmark Pharmaceuticals reported a return on equity of 28.08%, which is above the 14.93% average of its named peers in this comparison.”}}, {“@type”: “Question”, “name”: “Should I invest in Glenmark Pharmaceuticals based on its sector position?”, “acceptedAnswer”: {“@type”: “Answer”, “text”: “Glenmark Pharmaceuticals’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.”}}]}